SCHEMBL21065686

SCHEMBL21065686

c1ccc(-c2ccc(-c3nc(-c4ccc(-c5ccccc5)cc4)nc(-c4ccc(-c5cc(-c6ccccc6)c(-c6ccccc6)c(-c6ccccc6)c5-c5ccccc5)cc4)n3)cc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 7/20 0.48
KMT2A Q03164 7/20 0.48
MAPT P10636 3/20 0.48
HPGD P15428 3/20 0.48
ALDH1A1 P00352 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.47
NTSR1 P30989 1/20 0.44
LMNA P02545 2/20 0.42
KDM4E B2RXH2 1/20 0.42
GLA P06280 1/20 0.42
ADORA2A P29274 3/20 0.42
ADORA1 P30542 3/20 0.42
ADORA3 P0DMS8 2/20 0.42
ADORA2B P29275 2/20 0.42
POLB P06746 1/20 0.42
ALOX15 P16050 1/20 0.40
TSHR P16473 1/20 0.40
MAPK1 P28482 3/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22722745 1.00 MEN1 (0.48) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL22722744 0.98 MEN1 (0.50) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL22722796 0.94 MEN1 (0.44) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL18180830 0.94 MEN1 (0.44) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL24098353 0.93 MEN1 (0.43) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL22722729 0.93 MEN1 (0.43) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL21131898 0.93 MEN1 (0.43) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL22722660 0.93 MEN1 (0.43) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL22722731 0.93 MEN1 (0.43) MEN1KMT2AMAPTHPGDALDH1A1
SCHEMBL22722690 0.93 MEN1 (0.43) MEN1KMT2AMAPTHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11530201-B2 Triazine compounds substituted with bulky groups NOVALED GMBH (DE) 2022-12-20 US disclosed
US-11530201-B2 Triazine compounds substituted with bulky groups NOVALED GMBH (DE) 2022-12-20 US disclosed
US-10851056-B2 Compound for organic optoelectronic device, organic optoelectronic device and display apparatus SAMSUNG SDI CO., LTD. (KR) 2020-12-01 US disclosed
US-20200361916-A1 Triazine Compounds substituted with Bulky Groups SAMSUNG SDI CO. LTD. (KR) 2020-11-19 US disclosed
US-20200361916-A1 Triazine Compounds substituted with Bulky Groups SAMSUNG SDI CO. LTD. (KR) 2020-11-19 US disclosed
EP-3502106-B1 TRIAZINE COMPOUNDS SUBSTITUTED WITH BULKY GROUPS NOVALED GMBH (DE) 2020-09-02 EP disclosed
EP-3502106-B1 TRIAZINE COMPOUNDS SUBSTITUTED WITH BULKY GROUPS NOVALED GMBH (DE) 2020-09-02 EP disclosed
EP-3502106-A1 TRIAZINE COMPOUNDS SUBSTITUTED WITH BULKY GROUPS Novaled GmbH (DE) 2019-06-26 EP disclosed
EP-3502106-A1 TRIAZINE COMPOUNDS SUBSTITUTED WITH BULKY GROUPS Novaled GmbH (DE) 2019-06-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851056-B2 Compound for organic optoelectronic device, organic optoelectronic device and display apparatus OXER1, OR10J3, AOX1 MEN1 2402/4885KMT2A 3536/4885MAPT 2972/4885
US-11530201-B2 Triazine compounds substituted with bulky groups POU5F1, POU2F1, IKZF2 MEN1 1203/4885KMT2A 465/4885MAPT 3013/4885
US-20200361916-A1 Triazine Compounds substituted with Bulky Groups POU5F1, POU2F1, IKZF2 MEN1 1203/4885KMT2A 465/4885MAPT 3013/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.